LEO Pharma announce the completion of the Phase III FIELD Study 1, evaluating one year treatment outcomes of actinic keratosis

LEO Pharma has announced the completion of the Phase III FIELD Study 1 - the largest[1-3] ever, one year evaluation of field treatment with ingenol mebutate gel for actinic keratosis (AK) after initial cryosurgery of individual AK lesions, compared to cryosurgery followed by a vehicle gel. The study involved more than 300 patients across 35 trial sites and is also the first to evaluate field treatment with ingenol mebutate gel subsequent to cryosurgery. LEO Pharma reported that the study met its efficacy and safety endpoints at 11 weeks and 12 months...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Dermatology Source Type: news